Sabine Haggenburg
Overview
Explore the profile of Sabine Haggenburg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haggenburg S, Garcia Garrido H, Kant I, Van der Straaten H, de Boer F, Kersting S, et al.
Vaccines (Basel)
. 2023 Jul;
11(7).
PMID: 37515017
Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults. Therefore, most guidelines recommend vaccination with the 13-valent...
2.
Hofsink Q, Haggenburg S, Lissenberg-Witte B, Broers A, van Doesum J, van Binnendijk R, et al.
EClinicalMedicine
. 2023 Jun;
61:102040.
PMID: 37337616
Background: Patients with haematological malignancies have impaired antibody responses to SARS-CoV-2 vaccination. We aimed to investigate whether a fourth mRNA COVID-19 vaccination improved antibody quantity and quality. Methods: In this...
3.
Haggenburg S, Hofsink Q, Rutten C, Nijhof I, Hazenberg M, Goorhuis A
Semin Hematol
. 2023 Feb;
59(4):192-197.
PMID: 36805887
Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine...
4.
Haggenburg S, Hofsink Q, Lissenberg-Witte B, Broers A, van Doesum J, van Binnendijk R, et al.
JAMA Oncol
. 2022 Aug;
8(10):1477-1483.
PMID: 35951338
Importance: It has become common practice to offer immunocompromised patients with hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are scarce. Objective: To assess whether a third...
5.
Blok S, Haggenburg S, Collard D, van der Linden E, Galenkamp H, Moll van Charante E, et al.
J Hypertens
. 2022 May;
40(5):897-907.
PMID: 35506279
Background: Socioeconomic status (SES) and ethnicity are both important determinants of hypertension prevalence and control rates but their separate contribution is unknown. We assessed the association of SES with hypertension...
6.
Garcia Garrido H, Haggenburg S, Schoordijk M, Meijer E, Tanck M, Hazenberg M, et al.
Am J Hematol
. 2022 Feb;
97(5):592-602.
PMID: 35147238
The optimal schedule of pneumococcal vaccination after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains controversial. The objective of this study was to investigate the immunogenicity of a 5-dose pneumococcal vaccination...
7.
Haggenburg S, Lissenberg-Witte B, van Binnendijk R, Den Hartog G, Bhoekhan M, Haverkate N, et al.
Blood Adv
. 2022 Feb;
6(5):1537-1546.
PMID: 35114690
Vaccination guidelines for patients treated for hematological diseases are typically conservative. Given their high risk for severe COVID-19, it is important to identify those patients that benefit from vaccination. We...
8.
Draijer L, Haggenburg S, Benninga M, Chegary M, Koot B
Acta Paediatr
. 2020 Apr;
109(11):2388-2393.
PMID: 32271954
Aim: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent liver disease that affects 34% of children with obesity. Besides the liver-related morbidity, NAFLD also increases the risk of cardiometabolic...